InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: None

Monday, 10/25/2021 10:26:54 PM

Monday, October 25, 2021 10:26:54 PM

Post# of 42748
Lenzilumab is variant agnostic so its efficacy will not be affected by mutations.

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

https://www.nature.com/articles/s41423-021-00779-5